Thalidomide for prevention of camrelizumab‐induced reactive cutaneous capillary endothelial proliferation

OBJECTIVES: The study evaluated the efficacy of thalidomide in prevention of camrelizumab‐induced reactive cutaneous capillary endothelial proliferation (RCCEP). METHODS: In this study, patients treated with camrelizumab plus thalidomide or camrelizumab alone were included. The occurrences, onset ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Geng, Zhang, Fei‐Fei, Cheng, Huai‐Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313837/
https://www.ncbi.nlm.nih.gov/pubmed/35229882
http://dx.doi.org/10.1111/ajd.13812
Descripción
Sumario:OBJECTIVES: The study evaluated the efficacy of thalidomide in prevention of camrelizumab‐induced reactive cutaneous capillary endothelial proliferation (RCCEP). METHODS: In this study, patients treated with camrelizumab plus thalidomide or camrelizumab alone were included. The occurrences, onset time, severity of RCCEP and the adverse effect of thalidomide were analysed. RESULTS: A total of 19 patients were enrolled. The incidence of RCCEP in thalidomide group (2/9, 22.2%) was significantly lower than that in camrelizumab group (8/10, 80%). The median onset time of RCCEP was 5 weeks and 4 weeks respectively. The adverse events of thalidomide were mild, and no treatment‐associated interruption was observed. CONCLUSIONS: Thalidomide showed a promising in prevention of the RCCEP in patients receiving camrelizumab therapy with an acceptable safety profile.

Ejemplares similares